Anti Hypertensive Drugs Companies

Top Industry Leaders in the Anti Hypertensive Drugs Market

Antihypertensive Drugs Key Companies Latest AntiHypertensive Drugs Companies Update

Sep 2023
In a phase 2 randomized controlled study, persons with uncontrolled hypertension who received once-daily therapy with the specific aldosterone synthase inhibitor lorundrostat (Mineralys Therapeutics) had a safe and significant reduction in blood pressure. The medicine lowered seated automated workplace systolic blood pressure significantly more than placebo eight weeks following adding lorundrostat (50 mg or 100 mg once daily) or placebo (−9.6 mm Hg with 50 mg; −7.8 mm Hg with 100 mg), with the strongest effects observed in adults with obesity. Overproduction of aldosterone is linked to excessive blood pressure in persons with obesity and related conditions like metabolic syndrome and obstructive sleep apnea.

Nov 2023Additional results for aprocitentan, Idorsia's experimental dual endothelin receptor antagonist, which is used to treat people who have resistant hypertension, were presented orally, according to a statement released by Idorsia Ltd. Patients with hypertension can frequently successfully manage their blood pressure by taking medicine as prescribed and leading a healthy lifestyle. However, 10% of individuals develop resistant hypertension, which is characterized by high blood pressure even after taking at least three antihypertensive drugs at recommended dosages that belong to various pharmacological groups, including a diuretic. Aprocitentan has been shown in the Phase 3 PRECISION research to be safe and effective in lowering blood pressure (BP) in patients with resistant hypertension who are using at least three distinct classes of antihypertensive medicines, including diuretics.

List of AntiHypertensive Drugs Key companies in the market